Middle-aged Women With Adverse Pregnancy Outcomes and Heart Failure With Preserved Ejection Fraction

Status: Recruiting
Location: See location...
Intervention Type: Other, Diagnostic test
Study Type: Observational
SUMMARY

Due to the steady increase in the burden of HFpEF, especially in women, it is an important task to search for new markers and early predictors associated with the development of this disease. Nowadays, the relationship of adverse pregnancy factors with the development of long-term cardiac pathology, in particular, HFpEF, has not been completely established. One of the most significant issue is studying the younger phenotype of women. The goal of this observational analytical cross-sectional study is to study the relationship of heart failure with a preserved ejection fraction in middle-aged women with adverse pregnancy outcomes in the history of pregnancy. Research question: is there an association between adverse pregnancy factors and the development of HF in middle-aged women? Objectives 1. To assess the frequency of detection of APOs in the history of pregnancy in middle-aged women, depending on the presence or absence of HFpEF. 2. To compare clinical and anamnestic data, morphological and functional parameters of the heart in middle-aged women with the presence and absence of HFpEF. 3. To establish an association between APOs and the development of HFpEF in the long-term period in middle-aged women. 4. To identify mediators between the presence of APOs and the development of HFpEF in middle-aged women. Study population - 45-60 year-old women with the history of pregnancy (\>20 weeks) in the absence of low left ventricle ejection fraction (\<50%) Primary endpoint: The prevalence of HFpEF in patients with the history of APOs.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 45
Maximum Age: 60
Healthy Volunteers: f
View:

• All patients who administer to the Federal State Budgetary Institution National Medical Research Center for Therapy and Preventive Medicine, who are undergoing echocardiography for medical reasons

• Pregnancy \>20 weeks in the anamnesis

• Signed informed consent to participate in the study

Locations
Other Locations
Russian Federation
National Medical Research Center for Therapy and Preventive Medicine
RECRUITING
Moscow
Contact Information
Primary
Max Shperling, MD
MaxCardio@yandex.ru
+79118170034
Backup
Olga Dzhioeva, MD, PhD
odzhioeva@gnicpm.ru
+79166141821
Time Frame
Start Date: 2024-03-18
Estimated Completion Date: 2025-01
Participants
Target number of participants: 100
Treatments
Patient with the history of pregnancy
Patient with the history of pregnancy (1 or more \> 20 weeks)~This group will further be subdivided in a subgroup with HFpEF and a group without HFpEF
Sponsors
Leads: National Medical Research Center for Therapy and Preventive Medicine

This content was sourced from clinicaltrials.gov